Aims: We aimed to assess the utility of validated metabolomic-based non-invasive tests to estimate the prevalence of liver disease in overweight/obese T2DM patients.
Materials and Methods: A total of 97 T2DM patients with HbA1c <7% and BMI >25 kg/m2 were recruited. Patients underwent routine lab, liver ultrasound and FibroScan. OWLiver® Care test and OWLiver® test were measured (two serum-based, BMI-dependent lipidomic tests that discriminate between normal liver and NAFLD, and between isolated steatosis and NASH, respectively).
Results: Based on results from ultrasound and FibroScan, patients were divided into four groups (Table). The prevalence of NAFLD and NASH was 86.4% and 31.1%, respectively. Severe fibrosis (F2-F4) was found in 22.9% and cirrhosis (F4) in 12.2%. OWLiver® Care test classified correctly 95% of patients with NAFLD (AUC 0.929). It showed high sensitivity (95%) and high accuracy (80%). OWLiver® test showed high consistency with the results of ultrasound and FibroScan, classifying correctly 90% of the samples of patients with NASH.
Conclusions: The prevalence of NAFLD and NASH is high in overweight/obese T2DM patients. OWLiver® Care test and OWLiver® test can be good tools for early detection of NAFLD and NASH, respectively, in routine clinical practice.
V. Bellido: None. I. Martínez-Arranz: Employee; Self; OWL Metabolomics. I. Goicolea: None. A. Amor: None. J. Pi: None. A. Pérez: None. J. Espiga: Consultant; Self; Novo Nordisk A/S. C. Montalban: None. R. Mayo: Employee; Self; OWL Metabolomics. S. Gaztambide: None.